![]() Design Therapeutics Design Therapeutics is a biopharmaceutical company engaged the research and development of small-molecule gene targeted chimera therapeutic candidates. | ![]() Abliva Abliva is a biotech company that discovers and develops medicines for the treatment of mitochondrial disease. | ![]() Y-mAbs Therapeutics Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets. | |
Founding Date | Founding Date 2017 | Founding Date 2000 | Founding Date 2014 |
Type | Type Public | Type Subsidiary | Type Public |
Tags | |||
Locations | Locations Carlsbad, US HQ | Locations Lund, SE HQ | Locations New York, US HQ Copenhagen, DK Nutley, US |
Employees | Employees 54 | Employees 950% increase | Employees 3239% increase |
Valuation ($) | Valuation ($) 313.1 m | Valuation ($) N/A | Valuation ($) 657 m |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $87.7m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $15m (FY, 2024) |
Gross profit | Gross profit N/A | Gross profit kr497k (FY, 2024) | Gross profit $72.7m (FY, 2024) |
Net income | Net income ($69.8m) (FY, 2025) | Net income (kr90m) (FY, 2024) | Net income ($29.7m) (FY, 2024) |
Funding | |||
Total funding raised | Total funding raised $ 45m | Total funding raised $ 10.8m | Total funding raised $ 80m |

Abliva is a biotech company that discovers and develops medicines for the treatment of mitochondrial disease.
View company
Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets.
View company